Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg (OTHER 201068) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 25, 2026 , from http://ppman.hank.ai/transparency/procedure/201068/by-state?code_type=OTHER
“Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg (OTHER 201068) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/201068/by-state?code_type=OTHER. Accessed
October 25, 2026 .
“Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg (OTHER 201068) by State,” HANK Price Transparency ,
accessed October 25, 2026 ,
http://ppman.hank.ai/transparency/procedure/201068/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
201068 — Injection, Nivolumab And Relatlimab-rmbw, 3 Mg/1 Mg
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$40,304
National median
$14,431 – $57,270
IQR (p25 – p75)
4
hospitals filing
1
states
Walking in without insurance?
Cash / self-pay price
Cash median
$18,097
vs. negotiated
-55.1%
Hospitals reporting
4
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 201068 (OTHER), with interquartile range
State Median p25 p75
IN $40,304 $14,431 $57,270